UNSPSC 51412006: Imolamine

This classification denotes a vasodilating agent with the molecular formula C14H20N4O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K5F4RU5VQJ, chemically known as 4-(2-(diethylamino)ethyl)-5-imino-3-phenyl-delta(sup 2)-1,2,4-oxadiazoline but generally known as imolamine, which bears US NIH Compound Identifier 27501. European Medicines Agency schedules Imolamine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08156MIG.

UNSPSC 51412006 Imolamine, a Commodity code, encompasses pharmaceutical active ingredients and finished medications sourced by state and local health agencies, fire rescue services, and health benefit programs for clinical use. Recent solicitations show state and local governments buying advanced life support medications, generic multi-source pharmaceuticals, and over-the-counter products through both direct procurement and cooperative purchasing arrangements. The City of Tampa Fire Rescue, state health and human services commissions, and multistate cooperative alliances are the primary issuing bodies active under this code, purchasing medications for emergency medical services, state employee and retiree health plans, and facility-based pharmacy operations. Vendors must typically supply products meeting FDA requirements, current Good Manufacturing Practices, Drug Supply Chain Security Act compliance, and OSHA Hazard Communication Standards, with medications warranted free from defects and expiration dates maintained at nine months or longer from acceptance.

Activity spans Florida, Texas, Minnesota, and Oregon, with recent opportunities showing both spot purchases and framework agreements. The City of Tampa issued IFB 26P00188 in April 2026 for advanced life support medications including Labetalol, Epinephrine, Adenosine, and Diltiazem vials, with a response date of April 8, 2026 and an estimated contract value of $40,000; the solicitation included a 5 percent Small Local Business Enterprise bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for generic multi-source pharmaceuticals and OTC products due March 26, 2026, requiring vendors to supply through three authorized wholesalers with contracts effective July 1, 2026 and a two-year initial term. The Texas Health and Human Services Commission issued an exploratory RFI in April 2026 seeking vendor capabilities for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, with no award value specified at the information-gathering stage.